New Jersey Overdose Deaths Plunge 22%, Reaching Lowest Level Since Before Pandemic

New Jersey has achieved a significant milestone in its battle against the opioid crisis, with drug overdose deaths falling to their lowest level since before the COVID-19 pandemic. According to provisional data released by the Centers for Disease Control and Prevention, 1,546 New Jersey residents died from drug overdoses in 2025—a 22% decline from the 1,983 deaths recorded in 2024.

The reduction outpaces the national average of 14% and represents a drop of more than 50% compared to the state's pandemic peak in 2022, when overdose fatalities surpassed 3,000. The trend is being driven primarily by a reduction in deaths involving opioids, according to CDC analysts tracking the data through the National Vital Statistics System.

A Turnaround Years in the Making

For public health officials who have watched the crisis devastate communities across the Garden State, the numbers represent validation of sustained investment in prevention, treatment, and harm reduction infrastructure.

"Obviously, we're very encouraged by the news and by the statistics that we're seeing," said Angelo Valente, executive director of Partnership for a Drug-Free New Jersey. "However, we understand this is still a major issue in New Jersey and throughout the country and we need to continue to provide people with support and get to a point where there's not even one family affected by this."

The 22% decline places New Jersey among the states seeing the steepest reductions in overdose mortality. Rhode Island leads the nation with a 35% decrease, while nine states saw either increases or no change at all, according to the CDC's provisional data released June 17, 2026.

Nationally, overdose deaths fell nearly 14% from approximately 81,000 to 69,973 for the 12-month period ending January 2026. The latest CDC projections estimate 69,147 drug overdose deaths once all remaining data is incorporated—a 13.2% decline compared to the previous year.

The Paradox of Progress

Yet even as fatalities decline, the underlying prevalence of substance use disorders continues to climb. The percentage of Americans aged 12 or older with a drug use disorder in the past year increased from 8.7% in 2021 to 9.8% in 2024, according to the 2024 National Survey on Drug Use and Health conducted by SAMHSA.

This paradox—fewer deaths despite more people struggling with addiction—suggests that harm reduction strategies, expanded access to naloxone, and improved treatment pathways are successfully preventing fatalities even as substance use itself remains widespread. The data implies that people are using drugs more safely, accessing reversal medications when overdoses occur, or entering treatment before fatal outcomes.

Federal Funding Cuts Threaten Momentum

The encouraging trends arrive amid significant uncertainty about the future of federal support for addiction services. The Trump administration has moved to cut federal funding for overdose prevention and addiction treatment programs, including a controversial April 2026 announcement that federal dollars can no longer be used to purchase or distribute fentanyl test strips or other drug testing kits.

The Substance Abuse and Mental Health Services Administration characterized the policy shift as an effort to "shift away from harm reduction and practices that facilitate illicit drug use." The president's proposed 2027 budget includes additional cuts to substance use disorder and overdose prevention programs.

Public health advocates warn that slashing funding now risks reversing the hard-won progress evident in the CDC data.

"The reason we're in a situation where we're seeing a decline is because so many people have become aware of the dangers of opiates and also for people in addiction, they've had access to services," Valente explained. "So, we have to continue to support and fund prevention and treatment programs in order to continue to see that decline."

The Drug Policy Alliance has launched a campaign urging lawmakers to protect funding for services including naloxone distribution, fentanyl test strips, addiction treatment, recovery supports, and mental health services. The organization characterizes the proposed cuts as sacrificing "Americans' safety and health to funnel billions into violence and warfare."

Looking Ahead

New Jersey's experience demonstrates that sustained public health investment can bend the mortality curve of the overdose crisis, even as the drug supply continues to evolve with emerging threats like medetomidine and nitazenes. The state's success also highlights the importance of comprehensive approaches that combine prevention education, harm reduction services, and expanded access to evidence-based treatment.

With 1,546 families still grieving lost loved ones in 2025 alone, advocates emphasize that the work is far from complete. But the trajectory offers hope that the worst phase of the crisis may be passing—and that strategic investment in public health infrastructure can save lives at scale.

The challenge now is maintaining that momentum amid shifting federal priorities and ensuring that the communities hardest hit by the crisis continue to receive the resources needed to sustain recovery and prevent future tragedies.